![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260929_uniQure_Therapeutic_Indications-768x512.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n uniQure<\/p>\n Event Type<\/strong><\/p>\n Long-Term Clinical Data Update<\/p>\n Modality<\/strong><\/p>\n AAV Gene Therapy<\/p>\n Asset<\/strong><\/p>\n Ifezuntirgene Inilparvovec (AMT-130)<\/p>\n Target<\/strong><\/p>\n Huntingtin (HTT)<\/p>\n Disease Area<\/strong><\/p>\n Huntington Disease<\/p>\n uniQure reported new 48-month data for ifezuntirgene inilparvovec, formerly AMT-130, in early manifest Huntington disease. Among 12 high-dose patients, cUHDRS decline was 44% slower than an updated propensity-matched external control but was not statistically significant (p=0.144); Total Functional Capacity decline was 61% slower (nominal p=0.008). A refreshed 36-month analysis in 15 high-dose patients showed 80% slowing on cUHDRS (nominal p=0.005) and 67% on TFC (nominal p=0.011). The signal is mixed: durable functional separation and dose response remain encouraging, but the longest cUHDRS analysis is small, externally controlled and nonsignificant.<\/p>\n The June 30 data cut covered 29 treated patients in the first two cohorts, including 17 high-dose and 12 low-dose recipients. Twelve patients in each dose group had reached 48 months. High-dose patients changed by -0.90 on cUHDRS versus -1.61 in the updated external control and by -0.37 on TFC versus -0.94. A post hoc analysis using the prior external-control construction produced nominally significant 48-month differences, underscoring the sensitivity of the result to comparator choice.<\/p>\n The updated ENROLL-HD control had 53% missingness at 48 months, and faster-progressing controls were more likely to discontinue follow-up. That could bias the external comparator toward slower progression, as the company argues; it could also make post hoc control substitution difficult to interpret. The new 48-month results were not included in the submitted BLA, which FDA had agreed could rely primarily on 36-month data from 12 high-dose patients under the accelerated-approval pathway.<\/p>\n Five high-dose participants, 17%, had treatment-related serious central-nervous-system inflammation; all were reported resolved. One low-dose participant died by suicide roughly five years after treatment, assessed by the investigator as unrelated. Mean cerebrospinal-fluid neurofilament light was 4% above baseline at 48 months in 11 high-dose patients.<\/p>\n TFC tracks work, household activity and self-care and therefore carries direct functional meaning. Its separation at four years is consequential. cUHDRS integrates motor, cognitive and functional domains and remains the primary four-year uncertainty: a 44% modeled slowing estimate with p=0.144 cannot be described as confirmatory despite a favorable point estimate.<\/p>\n A durable one-time gene therapy is especially vulnerable to attrition and survivor bias in long follow-up, but external-control methods do not neutralize those risks. The small treated cohort, nonrandomized European component, crossover in the U.S. study and changing matched-control construction weaken causal certainty. The 36-month signal is stronger statistically and remains the regulatory anchor; the four-year update tests durability rather than replacing that anchor.<\/p>\n Two interpretations remain plausible. The constructive view is that convergent TFC, dose-response and 36-month cUHDRS findings indicate durable huntingtin-lowering benefit, with control attrition obscuring the 48-month composite endpoint. The competing view is that the apparent magnitude is unstable when the comparator changes and may regress as follow-up matures. Randomized confirmatory TFC results, prespecified sensitivity analyses and stable neurofilament and safety trajectories would upgrade the thesis; loss of functional separation, inflammatory toxicity or failure to reproduce benefit in the confirmatory study would downgrade or falsify it.<\/p>\n uniQure develops one-time gene therapies. Huntington disease is caused by a pathogenic CAG expansion in HTT and produces progressive motor, cognitive and psychiatric decline. Ifezuntirgene inilparvovec uses an AAV5 vector delivered stereotactically to the striatum to express an engineered microRNA intended to lower huntingtin transcripts, including the toxic exon 1 fragment. Direct intracranial delivery may support durable exposure but adds procedural and inflammatory risk and is not reversible.<\/p>\n The update strengthens durability on the functional endpoint while weakening any simple narrative that every key measure remains statistically secure at four years. The correct reading is neither clinical failure nor definitive disease modification. The regulatory case rests on a stronger 36-month package and FDA alignment; the scientific case now depends on whether randomized confirmatory evidence reproduces TFC benefit without relying on a fragile external-control construction.<\/p>\n Signal Importance: 5 of 5. Signal Direction: mixed. Confidence in Facts: high for the company-reported data and disclosed methods. Confidence in Interpretation: moderate-low because the cohorts are small, the comparison is external and the key 48-month cUHDRS result is nonsignificant. Red-team conclusion: durability on TFC is real evidence, but control sensitivity and the nonsignificant composite endpoint prevent a stronger directional conclusion.<\/p>\n","protected":false},"excerpt":{"rendered":" uniQure reported new 48-month data for ifezuntirgene inilparvovec, formerly AMT-130, in early manifest Huntington disease. Among 12 high-dose patients, cUHDRS decline was 44% slower than an updated propensity-matched external control but was not statistically…<\/p>\n","protected":false},"author":1,"featured_media":3521,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[515,892,514],"class_list":["post-3515","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-amt-130","tag-huntington-disease","tag-uniqure"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3515"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3515\/revisions"}],"predecessor-version":[{"id":3526,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3515\/revisions\/3526"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3521"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n